Literature DB >> 14971772

Evaluation of a TG-43 compliant analytical dosimetry model in clinical 192Ir HDR brachytherapy treatment planning and assessment of the significance of source position and catheter reconstruction uncertainties.

E Pantelis1, P Papagiannis, G Anagnostopoulos, D Baltas, P Karaiskos, P Sandilos, L Sakelliou.   

Abstract

A simple, time efficient, analytical model incorporating heterogeneities and body dimensions around a point 192Ir source is generalized for accurate dosimetry around commercially available 192Ir brachytherapy sources. The generalized model was verified in dosimetry of a clinical 192Ir high dose rate prostate monotherapy application, involving 16 catheters and 83 source dwell positions, through comparison with corresponding treatment planning system data. The computational time efficiency and accuracy of the proposed model allowed the assessment of the impact that uncertainties in source dwell positions and catheter reconstruction may have on dose distributions, and how these could potentially affect the clinical outcome. Results revealed that a 0.1 cm catheter reconstruction uncertainty and a 0.15 cm source position uncertainty along the catheter lead to a dose uncertainty of less than 2% for doses lower than 200% of the prescribed dose, reaching up to 5% for points lying in close proximity to the catheters. These uncertainties were found to have no impact (less than 1%) on dose volume histogram results of both the planning target volume and the urethra. A catheter reconstruction uncertainty as high as 0.2 cm results in a dose uncertainty greater than 2%, reaching up to 9%, only for points inside the 150% contour. However, even in this case, the impact on dose volume histogram calculations is less than 3%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971772     DOI: 10.1088/0031-9155/49/1/004

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  4 in total

1.  The impact of prostate volume changes during external-beam irradiation in consequence of HDR brachytherapy in prostate cancer treatment.

Authors:  Markus Karl Alfred Herrmann; Tammo Gsänger; Arne Strauss; Tereza Kertesz; Hendrik A Wolff; Hans Christiansen; Hilke Vorwerk; Clemens Friedrich Hess; Andrea Hille
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

Review 2.  In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice.

Authors:  Gabriel P Fonseca; Jacob G Johansen; Ryan L Smith; Luc Beaulieu; Sam Beddar; Gustavo Kertzscher; Frank Verhaegen; Kari Tanderup
Journal:  Phys Imaging Radiat Oncol       Date:  2020-09-28

Review 3.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

4.  Prostate volume and implant configuration during 48 hours of temporary prostate brachytherapy: limited effect of oedema.

Authors:  Anna M Dinkla; Bradley R Pieters; Kees Koedooder; Niek van Wieringen; Rob van der Laarse; Arjan Bel
Journal:  Radiat Oncol       Date:  2014-12-11       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.